Latest News-I-Mab Mediaroom_Page

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Co...

2023-11-01 20:00 1569

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Compan...

2023-10-16 20:00 1784

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete...

2023-10-10 20:00 1473

I-Mab Announces Upcoming Participation at September Conferences

ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is...

2023-09-05 20:00 1445

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

* Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antib...

2023-08-17 18:00 4392

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a c...

2023-08-08 20:00 1692

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2023-07-05 20:00 1906

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

I-Mab Announces the Appointment of Raj Kannan as CEO

GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nas...

2023-06-22 20:00 2522

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger...

2023-05-26 05:01 2321

I-MAB Filed 2022 Annual Report on Form 20-F

GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasda...

2023-05-01 20:00 2170

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2023-04-26 21:16 2927

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the mul...

2023-04-25 13:46 1839

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2023-04-24 21:00 1958

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

* Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overal...

2023-03-31 18:30 4365

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...

2023-03-20 20:00 2012

MSCI ESG Updated I-Mab to "A" Rating

GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2023-03-07 21:02 1867

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2022-11-03 21:01 2288

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2022-09-13 20:00 2237

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patient...

2022-09-10 21:00 1928

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

* Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzo...

2022-08-30 18:00 2395